A. Wang

1 month ago | nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more

AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.

Jun 5, 2024 | onlinelibrary.wiley.com | Shaikha AlQahtani |Ramya Ramakrishnan |A. Wang |César Núñez

LETTER TO THE EDITOR Venetoclax use in a patient with ataxia telangiectasia and early T-cell precursor acute lymphoblastic leukemia Shaikha Alqahtani, Shaikha Alqahtani Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Search for more papers by this authorRamya Ramakrishnan, Ramya Ramakrishnan Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Search for more papers by this authorShuyu E , Shuyu E...